EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictors and Characteristics of Hair Loss Among Users of GLP ‐1 Receptor Agonists: A Cross‐Sectional Analysis

Yahya Argobi iD, Norah Saad Jadaan, Hind Bader Alshalhoob, Manar Saleh Alyousef, Ghaid Mohammed Alotaibi, Hussain Sami Alwesaibie, Ibtihal Sultan M Alshehri

Journal of Cosmetic Dermatology · 2026-04 · 25 (4)

DOI: 10.1111/jocd.70835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 31.03.2026. Verfasst von Yahya Argobi und 6 weiteren Autor:innen. Beteiligte Einrichtung: King Khalid University, Abha, Saudi Arabia. Hauptthemen laut MEDLINE: Alopecia, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The increasing use of GLP‐1 receptor agonists for weight loss and metabolic improvements has led to the recognition of various side effects. One potential, yet underexplored, adverse effect is hair loss. This study aims to investigate the frequency, characteristics, and predictors of hair loss in patients using GLP‐1RAs.

Methods

This cross‐sectional study, conducted uniquely in Saudi Arabia from January to June 2025, involved 254 participants who had used GLP‐1RAs (Mounjaro, Ozempic, Saxenda, or Victoza) for weight loss purposes. Data were collected through structured questionnaires, ensuring comprehensive coverage of demographic information, clinical characteristics, and details of hair loss, including timing, severity, and progression. The data analysis was conducted using SPSS v29.

Results

A total of 254 participants were included in the study, with the majority being female (71.3%) and an average age of 33.28 ± 9.73 years. Hair loss characteristics by injection type revealed no significant differences in prevalence ( p = 0.116). However, severe hair loss was significantly more common in Mounjaro (43.4%) and Saxenda (42.9%) users compared to other groups ( p < 0.001). Multivariable logistic regression analysis identified gender, marital status, and injection type as significant predictors of hair loss. Males were less likely to report hair loss compared to females (adjusted OR = 0.36, p = 0.003). Married participants had the highest odds of experiencing hair loss (adjusted odds ratio = 9.94, p = 0.004), and Mounjaro users had significantly higher odds of hair loss compared to the users of other injection types (adjusted odds ratio = 3.02, p = 0.009). The duration of injection use did not significantly predict hair loss, although a trend toward higher odds was noted for those using injections for 6–12 months (adjusted odds ratio = 3.50, p = 0.053).

Conclusion

Our study highlights the significant side effects of hair loss associated with GLP‐1RA therapy, particularly in female patients and those using Mounjaro. Although this type of hair loss is typically non‐scarring and reversible, it can lead to psychological distress and affect treatment adherence. These conclusions highlight the need for clinicians to be aware of this potential side effect and to provide appropriate support and guidance to their patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlopeciaGlucagon-Like Peptide-1 Receptor AgonistsHumansCross-Sectional StudiesMaleFemaleAdultSaudi ArabiaMiddle AgedWeight LossPrevalenceSeverity of Illness IndexYoung Adult

Stichwörter der Autor:innen

GLP‐1 receptor agonistsMounjaroclinical managementgender differenceshair losssemaglutideside effectstelogen effluviumtirzepatideweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • King Khalid University, Abha, Saudi Arabia.
  • Majmaah University, Al Majmaah, Saudi Arabia.
  • King Fahad Specialist Hospital, Saudi Arabia.
  • King Saud Bin Abdulaziz University for Health Sciences, Saudi Arabia.
  • Almoosa Specialist Hospital, Saudi Arabia.

ORCID-Profile: Yahya Argobi

Förderung

  • King Khalid University

Zitieren

APA

Argobi, Y., Jadaan, N. S., Alshalhoob, H. B., Alyousef, M. S., Alotaibi, G. M., Alwesaibie, H. S., & Alshehri, I. S. M. (2026). Predictors and Characteristics of Hair Loss Among Users of GLP ‐1 Receptor Agonists: A Cross‐Sectional Analysis. Journal of Cosmetic Dermatology, 25(4). https://doi.org/10.1111/jocd.70835

Vancouver

Argobi Y, Jadaan NS, Alshalhoob HB, Alyousef MS, Alotaibi GM, Alwesaibie HS, et al. Predictors and Characteristics of Hair Loss Among Users of GLP ‐1 Receptor Agonists: A Cross‐Sectional Analysis. Journal of Cosmetic Dermatology. 2026;25(4). doi:10.1111/jocd.70835

BibTeX
@article{Argobi2026,
  author = {Argobi, Yahya and Jadaan, Norah Saad and Alshalhoob, Hind Bader and Alyousef, Manar Saleh and Alotaibi, Ghaid Mohammed and Alwesaibie, Hussain Sami and Alshehri, Ibtihal Sultan M},
  title = {Predictors and Characteristics of Hair Loss Among Users of GLP ‐1 Receptor Agonists: A Cross‐Sectional Analysis},
  journal = {Journal of Cosmetic Dermatology},
  year = {2026},
  volume = {25},
  number = {4},
  doi = {10.1111/jocd.70835}
}
Kostenlos starten →